Rituximab Better than Fingolimod for Preventing Relapses in Multiple Sclerosis Patients.
Source MD
Preventing relapses for patients with highly active multiple sclerosis (MS) is more easily accomplished with rituximab than with fingolimod, according to findings published in the Annals of Neurology. Read on.
Preventing relapses for patients with highly active multiple sclerosis (MS) is more easily accomplished with rituximab than with fingolimod, according to findings published in the Annals of Neurology. Read on.